ValuEngine downgraded shares of Nuvectra Corporation (NASDAQ:NVTR) from a hold rating to a sell rating in a report issued on Monday morning.

A number of other equities research analysts have also weighed in on NVTR. TheStreet upgraded shares of Nuvectra Corporation from a d rating to a c- rating in a report on Monday, June 19th. Piper Jaffray Companies restated a neutral rating and issued a $14.00 price objective on shares of Nuvectra Corporation in a report on Thursday, July 6th. Finally, Zacks Investment Research upgraded shares of Nuvectra Corporation from a sell rating to a hold rating in a report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. Nuvectra Corporation presently has an average rating of Hold and an average price target of $13.00.

Shares of Nuvectra Corporation (NASDAQ:NVTR) traded up 1.13% during trading on Monday, reaching $13.44. 29,045 shares of the company’s stock traded hands. The company’s market cap is $143.79 million. Nuvectra Corporation has a 52-week low of $4.63 and a 52-week high of $13.49. The company’s 50-day moving average is $12.38 and its 200 day moving average is $12.38.

Nuvectra Corporation (NASDAQ:NVTR) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($1.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.14) by $0.07. The firm had revenue of $7.20 million during the quarter, compared to analyst estimates of $5.96 million. Nuvectra Corporation had a negative net margin of 232.31% and a negative return on equity of 56.68%. The business’s quarterly revenue was up 188.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.85) EPS. Equities analysts forecast that Nuvectra Corporation will post ($4.77) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/06/nuvectra-corporation-nvtr-rating-lowered-to-sell-at-valuengine.html.

In other news, CEO Scott F. Drees purchased 10,000 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average cost of $11.72 per share, for a total transaction of $117,200.00. Following the acquisition, the chief executive officer now directly owns 125,180 shares of the company’s stock, valued at approximately $1,467,109.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.60% of the company’s stock.

A number of large investors have recently bought and sold shares of NVTR. Wells Fargo & Company MN raised its holdings in Nuvectra Corporation by 0.7% during the 1st quarter. Wells Fargo & Company MN now owns 112,997 shares of the company’s stock valued at $772,000 after buying an additional 751 shares during the last quarter. FNY Partners Fund LP raised its holdings in Nuvectra Corporation by 15.1% during the 1st quarter. FNY Partners Fund LP now owns 98,200 shares of the company’s stock valued at $670,000 after buying an additional 12,900 shares during the last quarter. Rockefeller Financial Services Inc. raised its holdings in Nuvectra Corporation by 3.2% during the 2nd quarter. Rockefeller Financial Services Inc. now owns 107,523 shares of the company’s stock valued at $1,428,000 after buying an additional 3,338 shares during the last quarter. Essex Investment Management Co. LLC raised its holdings in Nuvectra Corporation by 42.1% during the 2nd quarter. Essex Investment Management Co. LLC now owns 202,623 shares of the company’s stock valued at $2,691,000 after buying an additional 60,034 shares during the last quarter. Finally, Hodges Capital Management Inc. raised its holdings in Nuvectra Corporation by 18.6% during the 2nd quarter. Hodges Capital Management Inc. now owns 227,807 shares of the company’s stock valued at $3,025,000 after buying an additional 35,706 shares during the last quarter. Institutional investors own 57.42% of the company’s stock.

Nuvectra Corporation Company Profile

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related stocks with our FREE daily email newsletter.